home · filing · 0001558370-24-009138
8-K filed June 13, 2024, 7:59 PM ET
ticker XLO
CIK 0001840233
leadership
confidence high
sentiment neutral
materiality 0.35
Xilio Therapeutics expands board to nine with two new directors
Xilio Therapeutics, Inc.
Board increased to nine directors; elected James Shannon, M.D. as Class I director (term expiring at 2025 annual meeting).
Elected Aoife Brennan, M.D. as Class III director (term expiring at 2027 annual meeting).
Dr. Shannon appointed to Nominating and Corporate Governance Committee; Dr. Brennan to Audit Committee.
Both directors to receive standard non-employee director compensation and enter standard indemnification agreement.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2024-06-13
Filed June 13, 2024, 7:59 PM ET
elected James Shannon, M.D., as a Class I director of the Company
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
James Shannon was elected as Class I Director at Xilio Therapeutics, Inc..
Action elected
Role Class I Director
Exact text from the filing
elected James Shannon, M.D., as a Class I director of the Company
View on SEC.gov
Source: SEC EDGAR
accession 0001558370-24-009138
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.